F S&P 500
5,243.75 -1.75 (-0.03%) F Dow Jones
39,556.00 -3.00 (-0.01%) F Nasdaq
18,276.25 -19.25 (-0.11%) E-mini Russell 2000 Index Futur
2,071.60 -0.90 (-0.04%) Petróleo
79.25 +0.13 (+0.16%) Oro
2,348.60 +5.60 (+0.24%)
Humacyte, Inc. (HUMA)
Fuera de horario:
Humacyte, Inc.
2525 East North Carolina Highway 54
Durham, NC 27713
United States
919 313 9633
https://www.humacyte.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 183
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Laura E. Niklason M.D., Ph.D. | Founder, President, CEO & Director | 899.25k | N/D | 1963 |
| Mr. Dale A. Sander | CFO, Chief Corporate Development Officer & Treasurer | 704.33k | N/D | 1960 |
| Dr. Heather Ledbetter Prichard Ph.D. | Chief Operating Officer | 647.78k | N/D | 1978 |
| Dr. Juliana L. Blum Ph.D. | Co-Founder & Executive Advisor | N/D | N/D | N/D |
| Ms. Sabrina Osborne | Executive Vice President of Business Strategy & People | N/D | N/D | N/D |
| Mr. William John Scheessele | Chief Commercial Officer | N/D | N/D | 1972 |
| Dr. Shamik J. Parikh M.D. | Chief Medical Officer | 514.72k | N/D | 1973 |
| Mr. Harold Alterson | Senior Vice President of Quality | N/D | N/D | N/D |
| Dr. Yang Cao M.D., Ph.D. | Chief Regulatory Officer | N/D | N/D | 1966 |
Descripción
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Gestión corporativa
La calificación ISS Governance QuickScore de Humacyte, Inc. a partir del 1 de mayo de 2024 es 8. Las puntuaciones principales son Auditoría: 8; Junta: 8; Derechos del accionista: 8; Compensación: 8.
